Mutation lanscape of acute myeloid leukemia in elderly patients
- Authors: Vinogradov A.V1,2, Rezaykin A.V1, Sazonov S.V1,3, Sergeev A.G1, Kapitonova M.Y4
-
Affiliations:
- Ural State Medical University
- Sverdlovsk Regional Clinical Hospital N 1
- Institute of Medical Cell Technologies
- University Malaysia Sarawak (UNIMAS)
- Issue: Vol 14, No 4 (2019)
- Pages: 19-24
- Section: Articles
- URL: https://genescells.ru/2313-1829/article/view/122189
- DOI: https://doi.org/10.23868/201912027
- ID: 122189
Cite item
Open Access
Access granted
Abstract
The molecular genetic landscape of acute myeloid leukemia (AML) have specific features in elderly patients, and these features correlates with hematopoietic progenitor cells senescence. Aim: to estimate the frequency of mutations in DNMT3A, FLT3, KIT, NPM1, NRAS, TP53 and WT1 genes in AML patients in elderly. Bone marrow and peripheral blood samples obtained from 54 AML patients aged over 60 years old. Distribution of the patients according to FAB-classification was as follows: AML M0 - 2, M1 - 6, M2 - 27, М3 - 2, M4 - 11, M5 - 1, M6 - 3, acute myelofibrosis - 1, blastic plasmacytoid dendritic cell neoplasm - 1. Detection of mutations in DNMT3A, FLT3, KIT, NPM1, NRAS, TP53 and WT1 genes performed by automatic direct sequencing technique. In the study group were more common patients with unfavorable (33.3%, n=18) and unspecified (42.6%, n=23) cytogenetics. The average frequency of functionally significant mutations in all investigated genes among the treated AML patients was 38.9% (n=21), including 3 cases (27.3%) with normal karyotype, 11 cases (61.1%) with unfavorable cytogenetics, 7 cases (30.4%) with unspecified karyotype. Average frequency of mutations in TP53 gene exons 4-11 was 20.0%, FLT3 gene exons 12-15 and 19-21 18.4%, DNMT3A exons 18-26 - 9.1%, NRAS gene exons 1-4 - 7.7%, KIT gene exons 7-12 and 16-19 - 5.9%, NPM1 gene exons 9-12 - 5.4% (n=2), DNMT3A - 9.1% (n=1). Multiple point mutations in investigated genes were detected in 11.1% AML specimens (n=6, usually FLT3 gene mutations, including FLT3 ITD in 4 cases). Additional gene mutations detection using direct sequencing allowed to clarify the prognostic stratification of AML from groups of unspecified and intermediate prognosis in 35.9% (n=10). In all cases, they were associated with an unfavorable prognosis. Thus, using of cytogenetic and additional molecular genetic research, a favorable prognosis of overall survival was established in 2 cases (3.7%), intermediate - in 9 cases (16.7%), unfavorable - in 27 cases (50.0%), and unspecified - in 16 (29.6%).
Keywords
Full Text
About the authors
A. V Vinogradov
Ural State Medical University; Sverdlovsk Regional Clinical Hospital N 1
Email: a.vinogradov@egov66.ru
Ekaterinburg, Russia
A. V Rezaykin
Ural State Medical University
Email: a.vinogradov@egov66.ru
Ekaterinburg, Russia
S. V Sazonov
Ural State Medical University; Institute of Medical Cell Technologies
Email: a.vinogradov@egov66.ru
Ekaterinburg, Russia
A. G Sergeev
Ural State Medical University
Email: a.vinogradov@egov66.ru
Ekaterinburg, Russia
M. Y Kapitonova
University Malaysia Sarawak (UNIMAS)
Email: a.vinogradov@egov66.ru
Malaysia
References
- Bullinger L., Dohner K., Dohner H. Genomics of Acute Myeloid Leukemia Diagnosis and Pathways. J. Clin. Oncol. 2017; 35(9): 934-46.
- Desai P., Mencia-Trinchant N., Savenkov O. et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Nat. Med. 2018; 24(7): 1015-23.
- Zink F., Stacey S.N., Norddahl G.L. et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 2017; 130: 742-52.
- Vardiman J.V., Thiele J., Arber D.A. et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-52.
- Arber D.A., Orazi A., Hasserjian R. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391-405.
- Виноградов А.В., Резайкин А.В., Салахов Д.Р. и др. Сравнительный анализ результатов типирования молекулярных повреждений гена NPM1 при острых миелоидных лейкозах с использованием прямого автоматического секвенирования и иммуногистохимического метода. Вестник Уральской медицинской академической науки 2013; 4: 124-7.
- Walter R.B., Othus M., Burnett A.K. et al. Significance of FAB subclassification of “acute myeloid leukemia, NOS” in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. Blood 2013; 121: 2424-31.
- Виноградов А.В., Резайкин А.В., Изотов Д.В. и др. Применение технологии прямого автоматического секвенирования для детекции мутаций генов ASXL1, DNMT3A, FLT3, KIT, NRAS, TP53 и WT1 при острых миелоидных лейкозах с неуточненным кариотипом. Вестник Уральской медицинской академической науки 2016; 4: 38-51.
- Виноградов А.В. Разработка технологии детекции мутаций генов CDKN2A/ARF, FLT3, KIT, NPM1, NRAS, TET2, TP53, WT1 при острых миелоидных лейкозах. Российский онкологический журнал 2013: 4: 34-5. (Vinogradov A.V. Technology development of CDKN2A/ARF, FLT3, KIT, NPM1, NRAS, TET2, TP53, WT1 gene mutations detection during acute myeloid leukemia. Russian Journal of Oncology 2013: 4: 34-5).
- Виноградов А.В., резайкин А.В., Сергеев А.Г. Детекция точечных мутаций в гене DNMT3A при острых миелоидных лейкозах методом прямого автоматического секвенирования. Бюллетень сибирской медицины 2015; 14(1): 18-23.
- Smith C.C., Wang Q., Chin C.S. et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia. Nature 2012; 485: 260-3.
- Verstraete K., Vandriessche G., Januar M. et al. Structural insights into the extracellular assembly of the hematopoietic Flt3 signaling complex. Blood 2011; 118: 60-8.
- Breitenbuecher F., Schnittger S., Grundler R. et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2009; 113: 4074-7.
- Szatkowski D., Hellmann A. The overexpression of KIT proto-oncogene in acute leukemic cells is not necessarily caused by the gene mutation. Acta Haematol. 2015; 133: 116-23.
- Heldin C.H., Lennartsson J. Structural and functional properties of platelet-derived growth factor and stem cell factor receptors. Cold Spring Harb. Perspect. Biol. 2013; 5(8): a009100.
- Виноградов А.В., Резайкин А.В., Сазонов С.В. и др. Клинико-патогенетическая характеристика мутаций генов DNMT3A, FLT3, KIT, NPM1, NRAS, TP53 и WT1 у больных острыми миелоидными лейкозами в возрастной группе 15-45 лет. Гены и клетки 2018; 14(3): 72-7.
- Dohner H., Dolnik A., Tang L. et al. Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care. Leukemia 2018; 32(12): 2546-57.
Supplementary files
